Zhejiang Huahai Pharmaceutical (SHA:600521) said four of its drugs were proposed for selection for twelfth batch of China's National Centralized Drug Procurement Program, according to a Monday disclosure on the Shanghai bourse.
The drugs are lamotrigine tablets, a treatment for epilepsy, iguratimod tablets, a treatment for active rheumatoid arthritis, hyper tension drug perindopril/amlodipine tablets (III) and mesalazine enteric-coated tablets, a drug for ulcerative colitis and Crohn's disease.